Committees, Task Forces and Professional Interest Communities

SITC Committees & Task Forces

Committees are established by the SITC Board of Directors to support the strategic plan of the organization. Committee co-chairs are appointed by the SITC Board of Directors to serve a two year term and will ascend to chair after one term as co-chair. Chairs will serve two-year terms. Committee members are appointed by the chair and serve two year terms renewable up to three terms.

26 total

Academy of Immuno-Oncology Nominating Committee  

The nominating committee reviews the nominations from membership for the Academy of Immuno-Oncology, which recognizes individuals who have made seminal contributions to move the field of cancer immunotherapy forward to the benefit of patients.

  last person joined one month ago

View Only

Advances in Cancer Immunotherapy Subcommittee  

The Advances in Cancer Immunotherapy™ (ACI) Committee oversees the planning and implementation of SITC’s regional introductory, CME-, CNE-, CPE- and MOC-certified programs created for the entire clinical cancer care team. The committee provides expert guidance to the appropriate audiences and timely content relevant to advancing patient care using FDA-approved immunotherapies.

  last person joined one month ago

View Only

Annual Program Committee  

The Annual Program Committee oversees the programming associated with the society’s annual scientific conference and the other associated courses known as the “Annual Meeting & Pre-Conference Programs.” The committee ensures that there is exceptional educational content, opportunity for meaningful scientific exchange, a cohesive schedule of events and value-added networking opportunities to best meet the needs of the broad range of attendees.

  last person joined 3 months ago

View Only

Awards Review Committee  

The Awards Review Committee oversees the selection of SITC non-education awards granted through competitive applications including SITC Fellowships, the SITC Sparkathon and other SITC awards. The committee ensures fair, unbiased selection of any person who will receive a benefit, financial or otherwise, from SITC as an award or fellowship winner.

  last person joined one month ago

View Only

Big Data and Data Sharing Committee  

The Data Sharing and Big Data Committee is working to address hurdles in the field that relate to the handling, accessibility, and utilization of large data sets for the purpose of advancing immunotherapeutic development. The Committee represents the society when requested and develops talking points for the Board of Directors when asked.

  last person joined one year ago

View Only

Biomarkers Committee  

The Biomarkers Committee provides expert guidance and insights on the state of the art in biomarker identification and application in the cancer immunotherapy setting, identifies current hurdles to further success and makes recommendations to the scientific community to more rapidly move the field forward, specifically pertaining to standardization and standards, validation of biomarkers identification and analysis, data and specimen sharing, and collaboration across disciplines by monitoring the advances in cancer Immunotherapy, emerging new technologies for measuring aspects of immunity and novel candidate biomarkers from early phase trials.

  last person joined 3 years ago

View Only

Biotech Committee  

The SITC Biotech Committee is working to design a robust and sustainable ecosystem for the Immuno-Oncology (IO) Biotech Community. The committee aims to harness the collective entrepreneurial spirit, intellectual power, and commitment of leaders in the biotech industry, financial, pharmaceutical, government, and academic sectors to accelerate the development of new IO agents to cure and prevent cancer.

  last person joined one month ago

View Only

Cancer Immunotherapy Guidelines Oversight  

The Cancer Immunotherapy Guidelines Oversight Committee oversees the development of new disease-specific guidelines and updates for existing guidelines that provide guidance on the appropriate treatment algorithms and recommended administration of FDA-approved cancer immunotherapies as well as mitigating and managing adverse event. The oversight committee maintains standards for the SITC Cancer Immunotherapy Guidelines Expert Panels to ensure the recommendations are unbiased, relevant and facilitate clinical decision-making leading to optimal patient care.

  last person joined one month ago

View Only

Cell Therapy Committee  

The Cell Therapy Committee monitors the society’s strategic activities in cellular therapy and advises the Board of Directors on strategies to address the current and future hurdles in the cell therapy field. Currently, the committee is charged with address four key hurdles related to opportunities for regulatory consensus and efficiencies, understanding and enhancing product efficacy, solid tumor cell therapy, and host factors.

  last person joined one year ago

View Only

Certification Task Force  

Certification Task Force

  last person joined 5 years ago

View Only

Communications Committee  

The Communications Committee sets the agenda of and supports SITC’s marketing and communication strategic direction. The committee provides insights about pertinent and timely organizational key messages by vetting newsworthy content and identifying key trends in the field. The committee also assists in selection of and/or serves as meeting correspondents who liaise with the SITC Education team.

  last person joined one year ago

View Only

Early Career Scientist Committee  

The Early Career Scientist (ECS) Committee oversees the activities of the organization specifically for those in the early stages of their career as well as activities directed to entice others to consider a career in cancer immunotherapy basic and translational research. The committee provides recommendations about how the society can provide opportunities to meet the needs of these early career professionals as well as develop those early in their career into the future leaders of the organization and of the scientific community.

  last person joined one month ago

View Only

Education & Training Committee  

The Education and Training Committee is responsible for informing and vetting education, training and other outreach activities in support of the society and its objectives to further the understanding of cancer immunotherapy to a broad audience. The committee identifies knowledge gaps of important stakeholders in the cancer community at large, suggests topics, projects and other outreach activities for development and prioritizes specific education, training and outreach activities for implementation.

  last person joined one month ago

View Only

Executive Council  

The Executive Council serves in an advisory role to the Board of Directors and its officers to promote the long-term interests and institutional memory of the society. The council is comprised of the past presidents of the society as well as the immediate outgoing at-large members of the Board of Directors.

  last person joined one month ago

View Only

Executive Council Nominating Subcommittee  

The Executive Council Nominating Subcommittee is responsible for recommending candidates to the Board of Directors for at-large directors and officers. The subcommittee also recommends prospective recipients of honorary awards granted by the society.

  last person joined one month ago

View Only

Finance Committee  

The Finance Committee is responsible for providing financial oversight for the society including: Review of the annual operating budget with staff prior to presentation to the Board; Review of the annual audit and tax form 990 with the independent auditor prior to presentation to the Board; Setting the long-range financial goals for the organization along with funding strategies necessary to achieve them; Creation of policies, procedures and other safeguards to protect the organization’s assets.

  last person joined one month ago

View Only

Global Access and Impact Committee  

As part of SITC’s strategic initiatives, the Global Access and Impact Committee works by convening stakeholders to develop strategies to overcome the challenges of science, education, policy, and infrastructure in order to promote immunotherapy utilization and access across the world. The committee represents the society when requested and develops talking points for the Board of Directors when asked. Learn more about the Global Access and Impact Committee efforts below.

  last person joined one year ago

View Only

Immunoscore Dissemination Committee  

The Immunoscore Dissemination Committee will support dissemination of SITC’s efforts and help advance Immunoscore into the field of oncology and identify data gaps needed to support integration into clinical staging. This new proposed committee will focus on the creation of a dissemination plan to create standardized materials and education to engage stakeholders (such as the commission on cancer) in order to help advance the concept of Immunoscore into cancer staging and practice.

  last person joined 4 years ago

View Only

Immunotherapy Resistance Committee  

The Immunotherapy Resistance Committee is convening stakeholders from across the field of immunotherapy to help develop unified definitions of immunotherapy resistance in order to support future drug development. The committee will conduct in-person meetings and teleconferences to develop various outputs. The committee represents the society when requested and develops talking points for the Board of Directors when asked.

  last person joined one year ago

View Only

Industry Committee  

The Industry Committee oversees the strategies and activities related to the industry and biotech members of the society. The committee aims to create networking, education and collaboration opportunities by providing a forum for those in industry to meet and discuss areas of interest that are particular to those involved in drug development and taking a product to market.

  last person joined one month ago

View Only

SITC Cancer Immunotherapy Guidelines Expert Panels

SITC Cancer Immunotherapy Guidelines Expert Panels are comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative.

The Expert Panels draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITCs clinical practice guidelines. 

The Expert Panels in the society are under the guidance of the Cancer Immunotherapy Guidelines Oversight Committee

13 total

Renal Cell Carcinoma Immunotherapy Guideline Expert Panel  

SITC's Renel Cell Carcinoma Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

  last person joined 7 months ago

View Only

Multiple Myeloma Immunotherapy Guideline Expert Panel  

SITC's Multiple Myeloma Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

  last person joined 8 months ago

View Only

Acute Leukemia Immunotherapy Guideline Expert Panel  

SITC's Acute Leukemia Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

  last person joined one year ago

View Only

Melanoma Immunotherapy Guideline Expert Panel  

SITC's Melanoma Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

 

View Only

Head & Neck Immunotherapy Guideline Expert Panel  

SITC's Head and Neck Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

 

View Only

Immune Effector Cell-Related Adverse Events Immunotherapy Guideline Expert ...  

SITC's Immune Effector Cell-Related Adverse Events Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

 

View Only

Hepatocellular Immunotherapy Guideline Expert Panel  

SITC's Hepatocellular Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

 

View Only

Non-Melanoma Skin Cancer Immunotherapy Guideline Expert Panel  

SITC's Non-Melanoma Skin Cancer Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

 

View Only

Lung Cancer & Mesothelioma Immunotherapy Guideline Expert Panel  

SITC's Lung Cancer and Mesothelioma Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

 

View Only

Prostate Carcinoma Immunotherapy Guideline Expert Panel  

SITC's Prostate Carcinoma Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

 

View Only

Lymphoma Immunotherapy Guideline Expert Panel  

SITC's Lymphoma Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

 

View Only

Immune-Checkpoint Inhibitor-Related Adverse Events Immunotherapy Guideline ...  

SITC's Immune-Checkpoint Inhibitor-Related Adverse Events Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

 

View Only

Breast Cancer Immunotherapy Guideline Expert Panel  

SITC's Breast Cancer Immunotherapy Guideline Expert Panel is comprised of leaders in the immuno-oncology field who provide interdisciplinary perspectives including medical oncology, community oncology, radiation oncology, surgery, pathology, and nursing as well as other specializations, as necessary, and at least one patient advocate or representative. The Expert Panel draws from their own practical experience as well as evidence in the published literature and clinical trial data to develop the evidence- and consensus-based recommendations that are published in SITC's clinical practice guideline.

 

View Only

SITC Professional Interest Communities

SITC Professional Interest Communities are an original series of online communities created exclusively for SITC members who are researchers and clinicians in the cancer immunotherapy field to expand their network and receive career development support from colleagues.

Join a SITC Professional Interest Community to discuss your current and future research, scientific applications and career development needs, help colleagues address professional hurdles and build new relationships. SITC members of similar professional disciplines and experience will work together to identify and recommend ways their colleagues and the society can solve hurdles in the field.

SITC Professional Interest Communities exist in the following categories:

SITC Professional Interest Community Manual

Each Professional Interest Community must meet yearly criteria. Click below to review the required yearly outputs - View the Professional Interest Community Manual.

Membership Criteria

Any SITC member, current in their dues, may join a Professional Interest Community. Members can join as many communities as they like, at any time, through their SITC CONNECT accounts. Continued group participation is contingent upon maintaining a current SITC membership. Enrollment will automatically renew annually so long as SITC membership is current. Click here to become a SITC member.

Create Additional Professional Interest Communities

Any SITC member can propose additional Professional Interest Communities – focused on any professional theme that aligns with SITC’s mission – by submitting a SITC Professional Interest Community Proposal Form.

1 total

Women in Cancer Immunotherapy Network (July 2021)  

The Women in Cancer Immunotherapy Network (WIN) is a Society for Immunotherapy of Cancer (SITC) initiative seeking to promote and elevate women in the cancer immunotherapy field. Championed by SITC Past President Lisa H. Butterfield, PhD, the society's first female president, WIN provides a forum for women to discuss important topics relevant to their advancement in the field.

  last person joined 2 months ago

View Only